Hey Lyndon , I think Thomas is right , but the multiple tumour reduction early in a phase 1 is price sensitive info (you would think) and should be revealed to the market .
That meeting should be a good opportunity to glean some more info on the trials . Anybody going?
SBP
solbec pharmaceuticals limited
solbec investor briefing., page-3
Add to My Watchlist
What is My Watchlist?